Cell line · CVCL_1878
OCI-Ly19
Cancer cell line, Homo sapiens. Diffuse large B-cell lymphoma germinal center B-cell type. 36 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. OCI-Ly19. Cell lines, record CVCL_1878. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1878
On this page
Cell line
As Cellosaurus gives it.
- Name
- OCI-Ly19
- Accession
- CVCL_1878
- RRID
- RRID:CVCL_1878
- Synonyms
- OCI-LY19, OCI-LY-19, OCI-Ly 19, OCI Ly19, OCILY-19, OCILY19, OCILy19, Ly19, LY19
- Species
- Homo sapiens (Human)
- Sex
- Female
- Age at sampling
- 27Y
- Category
- Cancer cell line
- Diseases
- Diffuse large B-cell lymphoma germinal center B-cell type (NCIt C36080); Diffuse large B-cell lymphoma (ORDO Orphanet_544)
- Derived from
- Bone marrow (in situ)
- Entry created
- 2012-04-04
- Entry updated
- 2026-03-31
Source Cellosaurus
Problems1
| Problem | Cellosaurus's note |
|---|---|
| Caution | While it was indicated to be EBV-positive (PubMed=20454443), this result has later been shown to be invalid (personal communication of Uphoff, Cord C.). |
Source Cellosaurus
Papers36
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Mass Cytometry-Based Approach for the Investigation of Stimulator of Interferon Genes Pathway. | Eur J Immunol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. | Blood Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. | Cancer Cell | 2024 | Its Methods give the RRID and name the line | PubMed | |
| An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL. | Cell Rep Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. | Cell Rep Med | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. | Immunity | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Combination Treatment with GSK126 and Pomalidomide Induces B-Cell Differentiation in EZH2 Gain-of-Function Mutant Diffuse Large B-Cell Lymphoma. | Cancers (Basel) | 2020 | Its Methods give the RRID and name the line | PubMed | |
| IKKε and TBK1 in diffuse large B-cell lymphoma: A possible mechanism of action of an IKKε/TBK1 inhibitor to repress NF-κB and IL-10 signalling. | J Cell Mol Med | 2020 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 36
See all 36 papersRelatives0
None in this release.
Cell banks2
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1878
GET https://conductscience.org/api/cell-lines/v1/CVCL_1878/papers?page=2